An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Every thought, every movement, every heartbeat is controlled by lightning-quick electrical impulses in the brain, the muscles, and the heart. But too much electrical excitability in the membranes of the cells can cause things like epilepsy and cardiac arrhythmia. A research group at Linköping University has now published new discoveries that can lead to new medicines for these diseases.
Alcohol use in Bollywood movies is directly influencing the drinking habits of India's adolescents, according to a new study presented today at the World Congress of Cardiology in Dubai.
St. Jude Medical, Inc., a global medical device company, today announced CE Mark Approval of the Ellipse implantable cardioverter defibrillator (ICD). Designed with feedback from more than 200 physicians from around the world, the Ellipse ICD provides the benefits of advanced features and power in the industry's smallest high-energy ICD.
Boston Scientific Corporation announces the U.S. market launch of its Z Flex-270 Steerable Sheath. The device is intended for use in a wide range of electrophysiology (EP) procedures to facilitate the introduction and placement of diagnostic and therapeutic catheters within the heart.
Heart cells starved of nutrients are less likely to be damaged during periods of decreased blood flow and sudden influxes of blood, known as ischemia and reperfusion, and are also less likely to get out of synch with their cellular neighbors, the damaging phenomenon called arrhythmia.
Estech, a leader in minimally invasive and endoscopic cardiac ablation, announced today that the Food and Drug Administration (FDA) has given conditional Investigational Device Exemption (IDE) approval to initiate patient enrollment in the Estech-sponsored ATTAC-AF trial.
Cardiomyopathy comprises a deterioration of the heart muscle that affects the organ's ability to efficiently pump blood through the body. Previously researchers have tied forms of the disease to the alternative splicing of titin, a giant protein that determines the structure and biomechanical properties of the heart, but the molecular mechanism remained unknown.
High-fat, low-carb foods are a popular choice for dieters, but new laboratory research by University of Alabama at Birmingham cardiologists indicates these may be detrimental to the health of people who have ischemic cardiovascular disease or a predisposition to heart attacks.
XENTION LTD, the Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs, reported positive data today from a phase 1 trial of XEN-D0103 administered orally.
The Canadian Journal of Cardiology has published a focused update to the Canadian Cardiovascular Society's atrial fibrillation guidelines.
Biomedical Systems, a global provider of cardiac diagnostic services and products, has introduced the TruVue® Wireless Ambulatory ECG Monitoring System for the diagnosis and management of atrial fibrillation and other complex cardiac arrhythmia.
Boston Scientific Corporation announces the exercise of its option to acquire Cameron Health, Inc., a privately held company based in San Clemente, California.
As part of its continued commitment to ADHD research, Shire plc, the global specialty biopharmaceutical company, today announced it is initiating two Phase 4 clinical trials to compare Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) to Concerta (methylphenidate HCl) Extended-Release Tablets.
Pediatric cardiology researchers and clinicians from almost 50 centers from across the U.S. and around the world are gathering at the Cardiology 2012 Conference sponsored by The Children's Hospital of Philadelphia on Feb. 22-26 in Orlando, Fla.
How much calcium could a hibernating woodchuck's heart cells sequester, if a hibernating woodchuck's heart cells could sequester calcium? More than enough, it turns out, to protect the animals from cardiac arrhythmias - abnormal heart rhythms such as ventricular tachycardia and ventricular fibrillation that can lead to sudden cardiac death - according to a new study of the hibernating animals that may provide insight into arrhythmia therapies.
Researchers have found that a biological clock can influence a heart attack. The risk of “sudden cardiac death” peaks in the morning and rises again in the evening as shown in lab animals.
Dr. Ali Gheissari of Los Angeles, CA has been ranked among the top physicians in the nation based on patient reviews.
A fundamental discovery reported in the March 1st issue of the journal Nature, uncovers the first molecular evidence linking the body's natural circadian rhythms to sudden cardiac death (SCD). Ventricular arrhythmias, or abnormal heart rhythms, are the most common cause of sudden cardiac death: the primary cause of death from heart disease.
For the first time in a new U.S. clinical trial, researchers at Mount Sinai School of Medicine have used the HeartLight Endoscopic Ablation System (EAS) to correct abnormal electrical signals inside the heart of a patient affected by atrial fibrillation (AFib), one of the nation's most common heart ailments.
What we perceive as the beating of our heart is actually the co-ordinated action of more than a billion muscle cells. Most of the time, only the muscle cells from the larger heart chambers contract and relax. But when the heart needs to work harder it relies on back-up from the atrial muscle cells deep within the smaller chambers (atria) of the heart.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.